Cellectar Biosciences (NASDAQ:CLRB) focuses on developing innovative, targeted oncology treatments designed to improve the lives of patients battling cancer. With a keen emphasis on leveraging its proprietary phospholipid drug conjugate™ (PDC) platform, Cellectar aims to create more accurate and efficient therapeutic agents. The company's pipeline includes advanced projects like CLR 131, an investigational radioiodinated PDC therapy undergoing clinical trials for a range of malignancies including multiple myeloma and pediatric cancers. Through these ventures, Cellectar Biosciences is committed to achieving its core objective of advancing cancer treatment options to deliver improved outcomes and hope to patients and their families facing this tough journey.